Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07006636 · ClinicalTrials.gov registry record · NA
Effect of Watermelon on Cardiometabolic Health
A NA study, sponsored by University of California, Los Angeles.
- Not yet
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT07006636: Clinical Trial NA study, sponsored by University of California, Los Angeles.
NCT07006636 is a NA study that has not yet begun recruiting, run by University of California, Los Angeles. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07006636, a NA study, has not yet begun recruiting, sponsored by University of California, Los Angeles.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether consumption of 355 ml of watermelon juice will: 1. improve cardiovascular and overall metabolic health markers like blood pressure, heart rate, stiffness/flexibility of arteries (blood vessels), blood sugar, cholesterol), and gut hormones 2. contribute to the body's ability to protect itself from the potential cell damage caused by harmful chemical compounds (produced when skin is exposed to ultraviolet (UV) B light, for example). This will be evaluated by measuring how resistant skin is to the damage from UVB light exposure, as well as several markers of bodily stress blood and urine. This will be determined immediately after consuming the juice (to evaluate the effects the juice has on health right away), as well as after 4 weeks of daily juice consumption (to evaluate the effects the juice has on health when consumed consistently over time).
Primary Outcome
To determine the acute and chronic effects of WMJ consumption on cardiometabolic health, specifically focusing on postprandial blood pressure. Previous studies showed that watermelon extract improved blood pressure management in subjects with prehypertension and hypertension and reduced arterial stiffness in postmenopausal women. Postprandial blood pressure response is recently identified to be the most sensitive postprandial clinical feature in predicting subclinical atherosclerosis. However, n
Interventions
- OTHER Watermelon Juice + liquid meal test at baseline
- OTHER Sweetened placebo beverage +liquid meal test at baseline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-09-01 |
| Phase | NA |
What is known before NCT07006636 opens enrollment
NCT07006636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Watermelon Juice + liquid meal test at baseline is the first listed.
NCT07006636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07006636 about?
NCT07006636 is a clinical study titled "Effect of Watermelon on Cardiometabolic Health". The purpose of this study is to determine whether consumption of 355 ml of watermelon juice will: 1. improve cardiovascular and overall metabolic health markers like blood pressure, heart rate, stiffness/flexibility of arteries (blood vessels), blood sugar, cholesterol), and gut hormones 2. contrib...
What is the current status of trial NCT07006636?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2026-04-01. Estimated completion is 2027-09-01.
What interventions are being tested in trial NCT07006636?
The interventions under investigation include: Watermelon Juice + liquid meal test at baseline (OTHER), Sweetened placebo beverage +liquid meal test at baseline (OTHER).
Who is sponsoring clinical trial NCT07006636?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07006636's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI